NIKI
Price
$4.60
Change
-$0.26 (-5.35%)
Updated
Oct 2, 04:57 PM (EDT)
Capitalization
3.83M
Intraday BUY SELL Signals
SLGL
Price
$72.00
Change
-$1.00 (-1.37%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
227.38M
34 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NIKI vs SLGL

NIKI vs SLGL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NIKI vs. SLGL commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NIKI is a Hold and SLGL is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
NIKI vs SLGL: Fundamental Ratings
NIKI
SLGL
OUTLOOK RATING
1..100
123
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9297
PRICE GROWTH RATING
1..100
9238
P/E GROWTH RATING
1..100
2097
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NIKI's Valuation (43) in the Pharmaceuticals Major industry is in the same range as SLGL (75). This means that NIKI’s stock grew similarly to SLGL’s over the last 12 months.

NIKI's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SLGL (100). This means that NIKI’s stock grew similarly to SLGL’s over the last 12 months.

NIKI's SMR Rating (92) in the Pharmaceuticals Major industry is in the same range as SLGL (97). This means that NIKI’s stock grew similarly to SLGL’s over the last 12 months.

SLGL's Price Growth Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for NIKI (92). This means that SLGL’s stock grew somewhat faster than NIKI’s over the last 12 months.

NIKI's P/E Growth Rating (20) in the Pharmaceuticals Major industry is significantly better than the same rating for SLGL (97). This means that NIKI’s stock grew significantly faster than SLGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NIKISLGL
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (NIKI: $4.86 vs. SLGL: $73.00)
Brand notoriety: NIKI and SLGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NIKI: 8% vs. SLGL: 62%
Market capitalization -- NIKI: $3.83M vs. SLGL: $227.38M
NIKI [@Biotechnology] is valued at $3.83M. SLGL’s [@Biotechnology] market capitalization is $227.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NIKI’s FA Score shows that 1 FA rating(s) are green while SLGL’s FA Score has 0 green FA rating(s).

  • NIKI’s FA Score: 1 green, 4 red.
  • SLGL’s FA Score: 0 green, 5 red.
According to our system of comparison, NIKI is a better buy in the long-term than SLGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NIKI’s TA Score shows that 5 TA indicator(s) are bullish while SLGL’s TA Score has 4 bullish TA indicator(s).

  • NIKI’s TA Score: 5 bullish, 3 bearish.
  • SLGL’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, NIKI is a better buy in the short-term than SLGL.

Price Growth

NIKI (@Biotechnology) experienced а -3.95% price change this week, while SLGL (@Biotechnology) price change was +20.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

SLGL is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
NIKI
Daily Signal:
Gain/Loss:
SLGL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MDIA1.080.04
+3.85%
Mediaco Holding
ELMT20.350.39
+1.95%
The Elmet Group Co
FTAI167.320.29
+0.17%
FTAI Aviation Ltd
KC9.130.01
+0.11%
Kingsoft Cloud Holdings Limited
ABTS1.19-0.02
-1.65%
Abits Group Inc

NIKI and

Correlation & Price change

A.I.dvisor indicates that over the last year, NIKI has been loosely correlated with HLSQ. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NIKI jumps, then HLSQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NIKI
1D Price
Change %
NIKI100%
-0.82%
HLSQ - NIKI
60%
Loosely correlated
-3.99%
CANF - NIKI
48%
Loosely correlated
+0.45%
APVO - NIKI
46%
Loosely correlated
-3.30%
ICU - NIKI
45%
Loosely correlated
-4.82%
MLEC - NIKI
45%
Loosely correlated
-4.51%
More

SLGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLGL has been loosely correlated with TRAW. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SLGL jumps, then TRAW could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLGL
1D Price
Change %
SLGL100%
-1.72%
TRAW - SLGL
48%
Loosely correlated
-8.17%
NEUP - SLGL
36%
Loosely correlated
-1.40%
NIKI - SLGL
34%
Loosely correlated
-0.82%
GTBP - SLGL
33%
Poorly correlated
-4.17%
AVXL - SLGL
31%
Poorly correlated
-6.44%
More